SEC Fines Cassava $40M for Misleading Alzheimer’s Drug Trial Data

0
54

A shareholder class action filed earlier this year against Cassava, Barbier, and CFO Eric J. Schoen alleges the company denied manipulating data, but that its shares dropped by 15% when the City University of New York (CUNY) found evidence of potential scientific misconduct by Wang. Wang is not a defendant in that case.

SEC Fines Cassava $40M  : Legal Representation

Barbier and Burns are represented by attorneys from Jacobson Lopez LLP and BakerHostetler. Cassava is represented by Gibson Dunn & Crutcher LLP. Wang’s legal representation was not immediately available.